Do Not Increase to 75 mg - Discontinue Trazodone Instead
You should not increase trazodone from 50 mg to 75 mg because major clinical practice guidelines explicitly recommend against using trazodone at any dose for insomnia treatment. Both the 2017 American Academy of Sleep Medicine (AASM) and the 2020 VA/DoD guidelines advise against trazodone for chronic insomnia disorder 1, 2.
Why Guidelines Recommend Against Trazodone
The evidence base is clear and consistent:
Lack of efficacy: Systematic reviews found no significant differences between trazodone (50-150 mg) and placebo for sleep efficiency or discontinuation rates 2. While trazodone showed some improvement in subjective sleep quality, it failed to improve sleep onset latency, total sleep time, or wake after sleep onset 2.
Poor quality evidence: Studies were very short duration (mean 1.7 weeks) with follow-up of only 1-4 weeks 2. The low-quality evidence supporting efficacy was outweighed by the adverse effect profile 2.
Harms outweigh benefits: The AASM guideline specifically notes that for trazodone, "harms outweigh benefits" with only "moderate" quality evidence 1.
Specific Safety Concerns at Any Dose
The FDA label highlights serious risks that apply whether using 50 mg or 75 mg 3:
- Orthostatic hypotension and syncope - particularly problematic with dose increases
- Priapism - can cause irreversible erectile tissue damage
- Increased bleeding risk - especially with concurrent antiplatelet/anticoagulant use
- Cardiac arrhythmias - QT prolongation concerns
- Cognitive and motor impairment - affects ability to operate machinery
- Hyponatremia - particularly in elderly or those on diuretics
What to Do Instead
Switch to evidence-based alternatives that guidelines actually recommend 1:
First-line approach:
- Cognitive Behavioral Therapy for Insomnia (CBT-I) - superior to pharmacologic therapies 2
If pharmacotherapy needed:
- Low-dose doxepin (3-6 mg) - specifically approved for sleep maintenance insomnia with demonstrated efficacy in older adults 2, 1
- Nonbenzodiazepine BZRAs (zolpidem 10 mg, eszopiclone 2-3 mg, zaleplon 10 mg) - improve sleep efficiency, onset latency, and total sleep time 2, 1
- Suvorexant - for sleep maintenance insomnia 1
- Ramelteon 8 mg - for sleep onset insomnia 1
Common Pitfall to Avoid
Despite trazodone being one of the most commonly prescribed medications for insomnia in clinical practice 4, this represents a disconnect between evidence and practice. The 2024 meta-analysis confirms trazodone extends objective total sleep time by only 28 minutes but patients don't perceive increased sleep duration, and it's associated with significantly more adverse effects (RR = 1.18) and sleep-related adverse effects (RR = 4.31) 5.
The fact that your patient is requesting a dose increase suggests the current regimen isn't working - this is the perfect opportunity to transition to an evidence-based alternative rather than escalating an ineffective medication with known harms.
Practical Transition Strategy
- Taper trazodone gradually to avoid discontinuation syndrome (nausea, dizziness, irritability, insomnia) 3
- Simultaneously initiate low-dose doxepin 3-6 mg OR a nonbenzodiazepine BZRA at the lowest effective dose
- Counsel on risks of the new agent and use for shortest duration possible
- Refer for CBT-I as definitive long-term management
The 2025 meta-analysis emphasizes that while trazodone shows some benefit for sleep quality, "clinicians should prioritize risk stratification" and "integrate non-pharmacological interventions for long-term management" 6. Increasing to 75 mg moves in the wrong direction - away from evidence-based care.